Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.57 |
| ▸ | TSHR | P16473 | 3/20 | 0.52 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | HPGD | P15428 | 3/20 | 0.50 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | CASP1 | P29466 | 1/20 | 0.48 |
| ▸ | CASP7 | P55210 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15888700 | 0.95 | SMN1; SMN2 (0.54) | SMN1; SMN2TSHRRAB9AHPGDEPHX2 | |
| SCHEMBL15082721 | 0.95 | SMN1; SMN2 (0.54) | SMN1; SMN2TSHRRAB9AHPGDEPHX2 | |
| SCHEMBL15888730 | 0.93 | TSHR (0.59) | SMN1; SMN2TSHRRAB9AHPGDEPHX2 | |
| SCHEMBL15082333 | 0.93 | SMN1; SMN2 (0.52) | SMN1; SMN2TSHRRAB9AHPGDEPHX2 | |
| SCHEMBL27410517 | 0.91 | CASP2 (0.52) | SMN1; SMN2TSHRHPGDEPHX2 | |
| SCHEMBL29649591 | 0.88 | SMN1; SMN2 (0.50) | SMN1; SMN2TSHRRAB9AEPHX2KDM4E | |
| SCHEMBL16355251 | 0.88 | SMN1; SMN2 (0.47) | SMN1; SMN2TSHRRAB9AEPHX2ALDH1A1 | |
| SCHEMBL23711864 | 0.87 | SMN1; SMN2 (0.44) | SMN1; SMN2TSHRRAB9AHPGDEPHX2 | |
| SCHEMBL15046976 | 0.87 | MEN1 (0.59) | SMN1; SMN2TSHRRAB9AHPGDEPHX2 | |
| SCHEMBL16133369 | 0.87 | CASP2 (0.55) | SMN1; SMN2TSHRHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9393315-B2 | Compounds for targeting drug delivery and enhancing siRNA activity | NITTO DENKO CORPORATION (JP) | 2016-07-19 | — | — | US | disclosed |
| US-9393315-B2 | Compounds for targeting drug delivery and enhancing siRNA activity | NITTO DENKO CORPORATION (JP) | 2016-07-19 | — | — | US | disclosed |
| US-20130017249-A1 | COMPOUNDS FOR TARGETING DRUG DELIVERY AND ENHANCING siRNA ACTIVITY | NITTO DENKO CORPORATION (JP) | 2013-01-17 | — | — | US | disclosed |
| US-20130017249-A1 | COMPOUNDS FOR TARGETING DRUG DELIVERY AND ENHANCING siRNA ACTIVITY | NITTO DENKO CORPORATION (JP) | 2013-01-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130017249-A1 | COMPOUNDS FOR TARGETING DRUG DELIVERY AND ENHANCING siRNA ACTIVITY | LDLR, RARG, FABP4 | SMN1; SMN2 2548/4885TSHR 1224/4885RAB9A 1861/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.